ALZN:NSD-Alzamend Neuro Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.09

Change

0.00 (0.00)%

Market Cap

USD 0.10B

Volume

0.37M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

ALZN Stock Forecast & Price:
Based on the Alzamend Neuro Inc stock forecasts from 0 analysts, the average analyst target price for Alzamend Neuro Inc is not available over the next 12 months. Alzamend Neuro Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Alzamend Neuro Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Alzamend Neuro Inc’s stock price was USD 1.09. Alzamend Neuro Inc’s stock price has changed by -13.20% over the past week, +14.37% over the past month and -54.79% over the last year.

About Alzamend Neuro Inc (ALZN:NSD)

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic ...Read More

Company Website : https://www.alzamend.com

Address : 3500 Lenox Road NE, Atlanta, GA, United States, 30326

Employees : 4

Fiscal Year End : April

Currency: USD

Country : USA

Technical Indicators

52 Week High : 3.57

Short Ratio : 2.36

52 Week Low : 0.80

Shorted Shares : 1,328,851

200 Day Moving Average : 1.22

Shorted Shares Previous Month : 624,809

50 Day Moving Average : 1.02

Shares Held By Insiders : 50.51%

Short Percentage : 2.33%

Shares Held by Institutions : 3.25%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

N/A

 USD74.37B 13.87 10.84
VRTX Vertex Pharmaceuticals Inc

N/A

 USD71.91B 23.23 15.78
MRNA Moderna Inc

N/A

 USD48.37B 3.93 2.93
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

 USD31.55B 2.99 1.31
RPRX Royalty Pharma Plc

N/A

 USD28.36B 40.73 20.15
SGEN Seagen Inc

N/A

 USD26.11B 55.02 -36.54
ALNY Alnylam Pharmaceuticals Inc

N/A

 USD24.33B N/A -33.90
GMAB Genmab AS

N/A

 USD22.20B 42.20 3.93
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ALZN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -42.89% 61% D- 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.89% 61% D- 36% F
Trailing 12 Months  
Capital Gain -54.79% 65% D 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.79% 64% D 34% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -16.42% 36% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.42% 36% F 18% F
Risk Return Profile  
Volatility (Standard Deviation) 31.66% 77% C+ 53% F
Risk Adjusted Return -51.85% 33% F 21% F
Market Capitalization 0.10B 46% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.33 11% F 8% F
Price / Cash Flow Ratio -15.66 89% B+ 73% C
EV/EBITDA -7.85 88% B+ 79% C+
Management Effectiveness  
Return on Equity -98.61% 28% F 16% F
Return on Invested Capital -156.94% 12% F 11% F
Return on Assets -56.19% 14% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.36 62% D- 53% F
Short Percent 2.33% 61% D- 50% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.